Basic and clinical studies on SY5555 in the surgical field

• Published in: CHEMOTHERAPY Vol. 42; no. Supplement1; pp. 523 - 529
• Main Authors: Kunimatsu, Masahiko, Iwai, Shigetomi, Masuda, Hideki, Suda, Kiyomi, Cho, Ensyun, Sato, Fumii, Tabu, Mayumi, Tanaka, Takashi
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1994
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.42.Supplement1_523

We performed basic and clinical studies on SY5555. The antibacterial activity of SY5555 against clinical isolates was compared with that of cefaclor (CCL) and ofloxacin (OFLX). The MIC90 of SY5555 were> 100μg/ml for coagulase positive Staphylococcus (CPS), 1.56μg/ml for Escherichia coli, > 100μg/ml for Pseudomonas aeruginosa and 3.13μg/ml for Klebsiella pneumoniae. The antimicrobial activity of SY5555 was superior to that of CCL against CPS, E. coli and K. pneumoniae. SY5555 was administered at doses of 300 to 600 mg b. i. d. or t. i. d. to 26 patients with surgical infections (8 cases of infected atheroma, 5 of periproctal abscess, 3 of mastitis, 3 of secondary wound infection, 2 of anal fistula, 2 of furuncle and one case each of folliculitis, phlegmon and umbilical abscess). Clinical response was excellent in 3 cases, good in 20 cases, fair in 1 case and poor in 2 cases, an efficacy rate of 88.5%. No side effects were noted except for stomach discomfort and diarrhea in one case.